Fixed drug eruption induced by trimethoprim-sulfamethoxazole:: Evidence for a link to HLA-A30 B13 Cw6 haplotype

被引:53
作者
Özkaya-Bayazit, E
Akar, U
机构
[1] Istanbul Univ, Istanbul Fac Med, Dept Dermatol, Istanbul, Turkey
[2] Istanbul Univ, Istanbul Fac Med, Dept Med Biol, Istanbul, Turkey
关键词
D O I
10.1067/mjd.2001.117854
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background. Recent reports indicated a significant association between fixed drug eruption (FDE) and HLA class I antigens. A strong correlation was found between B22 antigen and feprazone-induced FDE. Objective: Our aim was to investigate the association between HLA class I antigens and FDE in Turkey,a country where feprazone is not oil the market and trimethoprim-sulfamethoxazole is most often the offending drug. Methods. HLA class I typing was performed by lymphocytotoxicity assay in 67 unrelated patients with FDE, all established by oral provocation. The frequencies are compared with those of 2378 control Subjects. Results: Significantly higher (P < .001) frequencies of the A30 antigen and A30 B13 Cw6 haplotype were found in 42 patients with FDE induced by trimethoprim-sulfamethoxazole. HLA-B55 (split of B22) was present exclusively in trimethoprim-sulfamethoxazole-induced FDE, and in higher frequency than in control subjects. Conclusion: To our knowledge, ours is the first report indicating a link between A-30 B13 Cw6 haplotype and trimethoprim-sulfamethoxazole-induced FDE. In addition, HLA-B22 was increased in patients with FDE caused by a drug other than feprazone.
引用
收藏
页码:712 / 717
页数:6
相关论文
共 28 条
  • [1] TOPICAL PROVOCATION OF FIXED DRUG ERUPTION
    ALANKO, K
    STUBB, S
    REITAMO, S
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 1987, 116 (04) : 561 - 567
  • [2] TOPICAL PROVOCATION OF FIXED DRUG ERUPTION - A STUDY OF 30 PATIENTS
    ALANKO, K
    [J]. CONTACT DERMATITIS, 1994, 31 (01) : 25 - 27
  • [3] ARCHER JR, 1990, SCAND J RHEUMATOL, P44
  • [4] BAUR MP, 1984, HISTOCOMPATIBILITY T, P677
  • [5] Complete sequence and gene map of a human major histocompatibility complex
    Beck, S
    Geraghty, D
    Inoko, H
    Rowen, L
    Aguado, B
    Bahram, S
    Campbell, RD
    Forbes, SA
    Guillaudeux, T
    Hood, L
    Horton, R
    Janer, M
    Jasoni, C
    Madan, A
    Milne, S
    Neville, M
    Oka, A
    Qin, S
    Ribas-Despuig, G
    Rogers, J
    Shiina, T
    Spies, T
    Tamiya, G
    Tashiro, H
    Trowsdale, J
    Vu, Q
    Williams, L
    Yamazaki, M
    [J]. NATURE, 1999, 401 (6756) : 921 - 923
  • [6] Breathnach S M, 1995, Australas J Dermatol, V36, P187, DOI 10.1111/j.1440-0960.1995.tb00970.x
  • [7] HLA AND ALLOPURINOL DRUG ERUPTION
    CHAN, SH
    TAN, T
    [J]. DERMATOLOGICA, 1989, 179 (01): : 32 - 33
  • [8] Gruen JR, 1997, BLOOD, V90, P4252
  • [9] FIXED DRUG ERUPTION - AN IMMUNOHISTOCHEMICAL INVESTIGATION OF THE ACUTE AND HEALING PHASE
    HINDSEN, M
    CHRISTENSEN, OB
    GRUIC, V
    LOFBERG, H
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 1987, 116 (03) : 351 - 360
  • [10] HLA HAPLOTYPES WITH C4B5 - EVIDENCE FOR FURTHER ALLELIC HETEROGENEITY
    HING, SN
    GILES, CM
    FIELDER, AHL
    BATCHELOR, JR
    [J]. IMMUNOGENETICS, 1986, 23 (03) : 151 - 155